Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, I-K | - |
dc.contributor.author | Lee, J-S | - |
dc.contributor.author | Zhang, S-N | - |
dc.contributor.author | Park, J. | - |
dc.contributor.author | Lee, K-M | - |
dc.contributor.author | Sonn, C. H. | - |
dc.contributor.author | Yun, C-O | - |
dc.date.accessioned | 2021-08-02T19:32:45Z | - |
dc.date.available | 2021-08-02T19:32:45Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2011-09 | - |
dc.identifier.issn | 0969-7128 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/27710 | - |
dc.description.abstract | The oncolytic adenovirus (Ad) is currently being advanced as a promising antitumor remedy as it selectively replicates in tumor cells and can transfer and amplify therapeutic genes. Interleukin (IL)-12 induces a potent antitumor effect by promoting natural killer (NK) cell and cytotoxic T cell activities. IL-18 also augments cytotoxicity of NK cells and proliferation of T cells. This effect further enhances the function of IL-12 in a synergistic manner. Therefore, we investigated for the first time an effective cancer immunogene therapy of syngeneic tumors via intratumoral administration of oncolytic Ad co-expressing IL-12 and IL-18, RdB/IL-12/IL-18. Intratumoral administration of RdB/IL-12/IL-18 improved antitumor effects, as well as increased survival, in B16-F10 murine melanoma model. The ratio of T-helper type 1/2 cytokine as well as the levels of IL-12, IL-18, interferon-gamma and granulocyte-macrophage colony-stimulating factor was markedly elevated in RdB/IL-12/IL-18-treated tumors. Mice injected with RdB/IL-12/IL-18 also showed enhanced cytotoxicity of tumor-specific immune cells. Consistent with these results, immense necrosis and infiltration of NK cells, as well as CD4(+) and CD8(+) T cells, were observed in RdB/IL-12/IL-18-treated tumor tissues. Importantly, tumors treated with RdB/IL-12/IL-18 showed an elevated number of T cells expressing IL-12R beta 2 or IL-18R alpha. These results provide a new insight into therapeutic mechanisms of IL-12 plus IL-18 and provide a potential clinical cancer immunotherapeutic agent for improved antitumor immunity. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGERNATURE | - |
dc.title | Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yun, C-O | - |
dc.identifier.doi | 10.1038/gt.2011.37 | - |
dc.identifier.scopusid | 2-s2.0-80052588142 | - |
dc.identifier.wosid | 000294685300007 | - |
dc.identifier.bibliographicCitation | GENE THERAPY, v.18, no.9, pp.898 - 909 | - |
dc.relation.isPartOf | GENE THERAPY | - |
dc.citation.title | GENE THERAPY | - |
dc.citation.volume | 18 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 898 | - |
dc.citation.endPage | 909 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Biotechnology & Applied Microbiology | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biotechnology & Applied Microbiology | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | GAMMA-INDUCING FACTOR | - |
dc.subject.keywordPlus | NATURAL-KILLER-CELLS | - |
dc.subject.keywordPlus | IFN-GAMMA | - |
dc.subject.keywordPlus | INTERFERON-GAMMA | - |
dc.subject.keywordPlus | DENDRITIC CELLS | - |
dc.subject.keywordPlus | COSTIMULATORY FACTOR | - |
dc.subject.keywordPlus | INTERLEUKIN (IL)-12 | - |
dc.subject.keywordPlus | GENE-THERAPY | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordAuthor | cancer immunogene therapy | - |
dc.subject.keywordAuthor | oncolytic adenovirus | - |
dc.subject.keywordAuthor | IL-12 | - |
dc.subject.keywordAuthor | IL-18 | - |
dc.subject.keywordAuthor | T cells expressing IL-12R beta 2 or IL-18R alpha | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.